USPTO issues new patent for OXiGENE benzosuberene-based compounds
The patent protects benzosuberene-based compounds including the analogues that are currently in preclinical development such as KGP18 and KGP156. OXiGENE chief executive officer Peter Langecker said issuance of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.